Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
95% CI 0.510.89) and worsening HF alone by 44% (HR = 0.56
With low cost Semaglutide and Tirzepatide, our patients are losing 15-22% of their body weight and feeling great about their bodies and confident in their clothes
Learn more about why you should not cut the Wegovy pills in half
The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months
/media/img/mt/2026/07/PeptideGoldRush/original.png){kind=icon}
US$ 29.03
US$ 23.89
US$ 24.55
